CLDN6 and neoplasm: For DSS, the higher expression of CLDN6 had a worse DSS in subgroup of age > 60 (Figure 8A), subgroup of weight > 80 (Figure 8B), subgroup of BMI > 30 (Figure 8C), subgroup of tumor invasion ≥ 50% (Figure 8D), subgroup of postmenopause (Figure 8E), subgroup of primary therapy outcome (CR) (Figure 8F), and subgroup of radiation therapy (No) (Figure 8G).